ACQUISITIONS AND INVESTMENTS - Additional Information (Details)
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
12 Months Ended |
|
|
|
Aug. 05, 2026 |
May 26, 2026
EUR (€)
Installment
|
Mar. 19, 2026
EUR (€)
|
Mar. 12, 2026
USD ($)
|
Mar. 12, 2026
EUR (€)
|
Feb. 26, 2026
USD ($)
|
Feb. 09, 2026
USD ($)
|
Feb. 06, 2026
USD ($)
shares
|
Jan. 15, 2026
USD ($)
$ / shares
|
Jan. 13, 2026
USD ($)
$ / shares
|
Nov. 30, 2025
EUR (€)
|
Oct. 31, 2025
USD ($)
|
Mar. 14, 2025
USD ($)
|
Mar. 31, 2026
USD ($)
|
Jun. 30, 2026
USD ($)
shares
|
Mar. 31, 2026
USD ($)
|
Mar. 31, 2026
shares
|
Dec. 31, 2025
USD ($)
shares
|
Jun. 30, 2025
USD ($)
|
Mar. 31, 2025
USD ($)
|
Jun. 30, 2026
USD ($)
shares
|
Jun. 30, 2025
USD ($)
|
Dec. 31, 2025
USD ($)
shares
|
Jan. 31, 2026
USD ($)
|
Jan. 13, 2026
EUR (€)
|
Mar. 14, 2025
£ / shares
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity method investment, ownership percentage required for significant influence |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.00%
|
|
|
|
|
|
20.00%
|
|
|
|
|
|
| Research and Development Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 227,480
|
|
|
|
$ 0
|
|
$ 294,980
|
$ 184,563
|
|
|
|
|
| Common stock, shares issued | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
240,548,960
|
|
|
92,816,561
|
|
|
240,548,960
|
|
92,816,561
|
|
|
|
| Nominal value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 749,905
|
|
|
|
|
|
| Change in fair value of convertible notes receivable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 288,535
|
|
|
|
(11,400)
|
|
1,362,338
|
(11,400)
|
|
|
|
|
| Principal amount outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31,726,775
|
|
|
|
|
|
$ 31,726,775
|
|
|
|
|
|
| Variable Interest Entity Ownership Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.90%
|
|
|
|
|
|
| Interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,093
|
|
|
|
160,952
|
|
$ 74,305
|
354,432
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
524,927
|
|
|
|
0
|
|
932,571
|
0
|
|
|
|
|
| Net Income (Loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6,475,862)
|
$ (459,898)
|
|
|
(12,224,975)
|
$ (16,611,425)
|
(6,935,760)
|
(28,836,400)
|
|
|
|
|
| Issuance of Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,090,785
|
2,150,836
|
|
|
|
|
|
|
|
|
|
|
| Change in fair value of derivative liability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(0)
|
|
|
|
(0)
|
|
(4,909,820)
|
(37,900)
|
|
|
|
|
| Reclassification of derivative liability in connection with amendment to Orbit Preferred Obligation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,505,010
|
|
|
|
|
|
|
|
|
|
|
| Gain on extinguishment of Orbit Preferred Obligation in excess of derivative liability fair value, recognized as a capital contribution (related party) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 784,807
|
|
|
|
|
|
|
|
|
|
|
| Installment Repayment | Installment |
|
60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issuance of Tekne Subordinated Convertible Note |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
928,000
|
|
|
|
|
|
| Gain on initial recognition of Tekne Investment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
$ 0
|
|
84,000
|
0
|
|
|
|
|
| Orbit Amendment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issuance of Common Stock |
|
|
|
|
|
|
$ 10,020,040
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Change in fair value of derivative liability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,909,820
|
|
|
|
|
|
| Reclassification of derivative liability in connection with amendment to Orbit Preferred Obligation |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,505,010
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gain on extinguishment of Orbit Preferred Obligation in excess of derivative liability fair value, recognized as a capital contribution (related party) |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 784,807
|
|
|
|
|
|
|
|
|
|
|
|
|
| Orbit preferred obligation in excess of derivative liability carrying value |
|
|
|
|
|
|
8,199,636
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Orbit preferred obligation in excess of derivative liability fair value |
|
|
|
|
|
|
$ 7,414,830
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lyocon Acquisition [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate purchase price |
|
|
|
|
|
|
|
|
$ 2,310,558
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business acquisition, cash paid |
|
|
|
|
|
|
|
|
$ 750,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
419,771
|
|
|
|
|
|
760,136
|
|
|
|
|
|
| Net Income (Loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6,353)
|
|
|
|
|
|
(13,819)
|
|
|
|
|
|
| Business acquisition date of acquisition agreement |
|
|
|
|
|
|
|
|
Jan. 15, 2026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to acquire ownership interest in cash |
|
|
|
|
|
|
|
|
$ 750,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Promissory notes, principal amount |
|
|
|
|
|
|
|
|
1,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument face amount |
|
|
|
|
|
|
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Potential earn out payment period |
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Funding written notice period |
|
|
|
|
|
|
|
|
30 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of earn-out entitled |
|
|
|
|
|
|
|
|
30.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Identifiable intangible assets |
|
|
|
|
|
|
|
|
$ 535,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of contingent consideration |
|
|
|
|
|
|
|
|
138,558
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lyocon Acquisition [Member] | Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument face amount |
|
|
|
|
|
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lyocon Acquisition [Member] | Short-Term Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument face amount |
|
|
|
|
|
|
|
|
250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lyocon Acquisition [Member] | Long-Term Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument face amount |
|
|
|
|
|
|
|
|
250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lyocon Acquisition [Member] | General and Administrative [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acquisition-related costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
308,169
|
|
|
|
|
|
| Lyocon Acquisition [Member] | Trade names / trademarks [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Identifiable intangible assets |
|
|
|
|
|
|
|
|
$ 62,770
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acquired intangible assets useful lives |
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lyocon Acquisition [Member] | Cash Earnout [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Contingent consideration liability |
|
|
|
|
|
|
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lyocon Acquisition [Member] | Cash Earnout [Member] | Minimum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Undiscounted amount to pay in earn-out |
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lyocon Acquisition [Member] | Cash Earnout [Member] | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Undiscounted amount to pay in earn-out |
|
|
|
|
|
|
|
|
1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tekne Transaction [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Escrow deposit amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,200,000
|
|
|
|
|
|
4,200,000
|
|
|
|
|
|
| Issuance of Tekne Subordinated Convertible Note |
|
|
|
|
|
|
|
|
|
$ 928,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gain on initial recognition of Tekne Investment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
84,000
|
|
|
|
|
|
| Tekne Transaction [Member] | Tekne Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Transfer of interest percentage |
|
2.90%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| H&K Investment Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate purchase price |
|
|
|
|
|
|
|
$ 15,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, shares issued | shares |
|
|
|
|
|
|
|
295,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of outstanding common shares |
|
|
|
|
|
|
|
0.80%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acquisition-related costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
$ 22,134
|
|
|
|
|
|
| January 2026 Tekne Agreements [Member] | Tekne Transaction [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity interest |
|
|
|
|
|
|
|
|
|
2.90%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.90%
|
|
| Provision for convertible receivable | € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 13,000,000
|
|
| Assets guaranteed |
|
|
|
|
|
|
|
|
|
$ 4,200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Advance of Tekne Convertible Note Receivable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,179,686
|
|
|
|
|
|
|
|
|
| January 2026 Tekne Agreements [Member] | Tekne Transaction [Member] | Letter of Credit [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash collateral |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 875,000
|
|
|
| Tekne Convertible Receivable [Member] | Tekne Transaction [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Provision for convertible receivable | € |
|
|
|
|
|
|
|
|
|
|
€ 13,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument, maturity date |
|
|
|
|
|
|
|
|
|
|
Jan. 13, 2027
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tekne Convertible Receivable [Member] | March 2026 Tekne Letter [Member] | Minimum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase of convertible receivable amount | € |
|
|
€ 13,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tekne Convertible Receivable [Member] | March 2026 Tekne Letter [Member] | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase of convertible receivable amount | € |
|
|
16,692,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tekne Convertible Receivable [Member] | May 2026 Tekne Letter [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase of convertible receivable amount | € |
|
€ 29,692,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GP Authorization [Member] | March 2026 Tekne Letter [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Capital increase amount | € |
|
|
€ 13,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest Acquisition [Member] | Tekne Transaction [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Effective interest rate |
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
| Conversion Price | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,394,790
|
|
|
|
|
|
|
|
|
|
| Maturity date |
|
|
|
|
|
|
|
|
|
Jan. 31, 2027
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jan. 31, 2027
|
|
| Subordinated convertible note principal amount |
|
|
|
|
|
|
|
|
|
$ 1,740,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Conversion price per share | $ / shares |
|
|
|
|
|
|
|
|
|
$ 1.25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lyocon Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business acquisition, cash paid |
|
|
|
|
|
|
|
|
$ 2,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Investment Agreement [Member] | May 2026 Tekne Letter [Member] | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase of convertible receivable amount | € |
|
29,692,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible note receivable cash payments | € |
|
12,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity Awards Equal to 0.07% of Market Cap [Member] | Lyocon Acquisition [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share price | $ / shares |
|
|
|
|
|
|
|
|
$ 3.49
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of consecutive trading days |
|
|
|
|
|
|
|
|
20 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of entitlement of equity awards to market cap |
|
|
|
|
|
|
|
|
0.07%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity Awards Equal to 0.10% of Market Cap [Member] | Lyocon Acquisition [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share price | $ / shares |
|
|
|
|
|
|
|
|
$ 4.99
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of consecutive trading days |
|
|
|
|
|
|
|
|
20 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of entitlement of equity awards to market cap |
|
|
|
|
|
|
|
|
0.10%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity Awards Equal to 0.15% of Market Cap [Member] | Lyocon Acquisition [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share price | $ / shares |
|
|
|
|
|
|
|
|
$ 9.98
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of consecutive trading days |
|
|
|
|
|
|
|
|
20 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of entitlement of equity awards to market cap |
|
|
|
|
|
|
|
|
0.15%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Developed Technology Rights [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Average useful life |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years 4 months 24 days
|
|
|
|
|
|
5 years 4 months 24 days
|
|
|
|
|
|
| Developed Technology Rights [Member] | Lyocon Acquisition [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Identifiable intangible assets |
|
|
|
|
|
|
|
|
$ 348,720
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acquired intangible assets useful lives |
|
|
|
|
|
|
|
|
8 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Customer Relationships [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Average useful life |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7 years 3 months 18 days
|
|
|
7 years
|
|
|
7 years 3 months 18 days
|
|
7 years
|
|
|
|
| Customer Relationships [Member] | Lyocon Acquisition [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Identifiable intangible assets |
|
|
|
|
|
|
|
|
$ 267,352
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acquired intangible assets useful lives |
|
|
|
|
|
|
|
|
8 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Orbit [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity method investment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 949,806
|
|
|
|
|
$ 949,806
|
|
|
|
| Aggregate purchase price |
|
|
|
|
|
|
|
|
$ 16,592,107
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business acquisition, cash paid |
|
|
|
|
|
|
|
|
2,000,000
|
|
|
|
|
|
|
|
|
1,500,000
|
|
|
|
|
|
|
|
|
| Proportionate share of net assets | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,112,750
|
|
|
|
| Business acquisition, consideration advance payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,750,000
|
|
|
|
| Settlement date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dec. 31, 2026
|
|
|
|
|
|
| Subscription for orbit shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,778,600
|
|
|
|
|
11,778,600
|
|
|
|
| Fair value of orbit preferred obligation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,028,600
|
|
|
|
| Deposit on acquisition |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 733,272
|
|
|
|
|
$ 733,272
|
|
|
|
| Interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 67,737
|
$ 0
|
|
|
|
|
| Equity interest previously held fair value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 890,398
|
|
|
|
|
|
890,398
|
|
|
|
|
|
| Equity remeasurement loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
59,408
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
105,156
|
|
|
|
|
|
172,435
|
|
|
|
|
|
| Net Income (Loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(830,249)
|
|
|
|
|
|
(918,756)
|
|
|
|
|
|
| Identifiable intangible assets |
|
|
|
|
|
|
|
|
$ (895,586)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acquisition-related costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
$ 212,360
|
|
|
|
|
|
| Purchase of ownership interest |
|
|
|
|
|
|
|
|
22.00%
|
|
|
10.70%
|
|
|
10.70%
|
|
|
|
|
|
10.70%
|
|
|
22.00%
|
|
|
| Orbit [Member] | Developed Technology Rights [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amortized years |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
5 years
|
|
|
|
| Identifiable intangible assets |
|
|
|
|
|
|
|
|
$ 2,092,320
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Orbit [Member] | Customer Relationships [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Identifiable intangible assets |
|
|
|
|
|
|
|
|
$ 139,488
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Orbit [Member] | Nuburu Defense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity method investment |
|
|
|
|
|
|
|
|
|
|
|
$ 5,000,000
|
|
|
|
|
|
$ 1,500,000
|
|
|
|
|
$ 1,500,000
|
|
|
|
| Equity method investment, final tranche closing date |
|
|
|
|
|
|
|
|
|
|
|
Oct. 07, 2028
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity method investment, ownership percentage required for amendment of bylaws |
|
|
|
|
|
|
|
|
|
|
|
20.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business acquisition, final tranche closing date |
|
|
|
|
|
|
|
|
|
|
|
Dec. 31, 2026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate purchase price |
|
|
|
|
|
|
|
|
|
|
|
$ 12,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business acquisition, cash paid |
|
|
|
|
|
|
|
|
|
|
|
3,750,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business combination, non-cash consideration |
|
|
|
|
|
|
|
|
|
|
|
$ 8,750,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exclusive rights period upon letter of intent |
|
|
|
|
|
|
|
|
|
|
|
36 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of ownership interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.70%
|
|
|
|
|
10.70%
|
|
|
|
| Orbit [Member] | Nuburu Defense [Member] | Alessandro Zamboni [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business acquisition, consideration advance payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,750,000
|
|
|
|
|
|
|
|
|
| Business acquisition, consideration offsetting credit payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,350,000
|
|
|
|
|
|
|
|
|
| Business combination, consideration, remaining advance payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,400,000
|
|
|
|
|
|
|
|
|
| NewCo [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of capital owned |
|
|
|
|
|
60.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SYME Strategic Investment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Inventory monetization advanced |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,668,545
|
|
|
|
| Nominal value |
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,150,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Conversion price per share | £ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
£ 0.000039
|
| SYME 3 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Variable Interest Entity Ownership Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100.00%
|
|
|
|
|
|
| Variable interest entity ownership, expected losses and residual returns percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100.00%
|
|
|
|
|
|
| SYME 3 [Member] | Bond Subscription Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issuance in variable rate bonds | € |
|
|
|
|
€ 30,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nominal value | € |
|
|
|
|
€ 5,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maturity date |
|
|
|
2029-03
|
2029-03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subscription price | € |
|
|
|
|
€ 4,824,294
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subscription price paid |
|
|
|
$ 5,668,545
|
€ 4,824,294
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] |
|
|
|
us-gaap:EurodollarMember
|
us-gaap:EurodollarMember
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Basis spread margin on variable rate |
|
|
|
7.50%
|
7.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cap rate |
|
|
12.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notice for redemption on bond payment date |
|
|
|
120 days
|
120 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Change in fair value of convertible notes receivable |
|
|
|
$ 5,718,059
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,780,227
|
|
|
|
|
|
| Principal amount outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,981,850
|
|
|
|
|
|
$ 5,981,850
|
|
|
|
|
|
| Discount on nominal amount | € |
|
|
|
|
€ 425,706
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lyocon [Member] | Lyocon Acquisition [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of ownership interest |
|
|
|
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tekne [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of ownership interest |
|
|
70.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.90%
|
|
|
| Tekne [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of ownership interest |
70.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Investment agreement, description |
expects to close the Tekne transaction and obtain a 70% controlling interest in Tekne on or about 30 days following receipt of the Golden Power regulatory approval or on such later date as may be mutually agreed upon in writing by the parties to the Investment Agreement.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tekne [Member] | March 2026 Tekne Letter [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to acquire ownership interest in cash | € |
|
|
€ 6,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of ownership interest |
|
|
70.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tekne [Member] | May 2026 Tekne Letter [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to acquire ownership interest in cash | € |
|
€ 5,200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of additional subject to obtaining interest |
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of ownership interest |
|
70.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tekne [Member] | Tekne Convertible Receivable [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of ownership interest |
|
|
|
|
|
|
|
|
|
|
27.90%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tekne [Member] | Tekne Convertible Receivable [Member] | March 2026 Tekne Letter [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible receivable interest rate |
|
|
32.10%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tekne [Member] | GP Authorization [Member] | March 2026 Tekne Letter [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of capital increase |
|
|
25.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of subject to obtaining interest |
|
|
60.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of additional subject to obtaining interest |
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tekne [Member] | Interest Acquisition [Member] | Tekne Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of ownership interest |
|
|
|
|
|
|
|
|
|
2.90%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.90%
|
|
| Tekne [Member] | Investment Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interim Funding Advance Amount | € |
|
€ 1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum additional amount | € |
|
€ 12,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of ownership interest |
|
70.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tekne [Member] | Investment Agreement [Member] | May 2026 Tekne Letter [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to acquire ownership interest in cash | € |
|
€ 5,200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of additional subject to obtaining interest |
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tekne [Member] | Majority Shareholder [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Variable Interest Entity Ownership Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.10%
|
|
|
|
|
|
| Maddox Joint Venture [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development funds |
|
|
|
|
|
$ 4,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of development funds |
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of capital owned |
|
|
|
|
|
40.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Joint venture, exclusive rights period |
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Joint venture term |
|
|
|
|
|
1 year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notice of non-renewal |
|
|
|
|
|
90 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Research and Development Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
$ 289,283
|
|
|
|
|
|
| Joint venture cash payments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 289,283
|
|
|
|
|
|
| Mr. D'Arrezzo [Member] | GP Authorization [Member] | March 2026 Tekne Letter [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of subject to obtaining interest |
|
|
2.90%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|